ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAMANAOAPAQARASATAUAVAWAXAYAZBABB
1
Deal DateR&DLicensor CategoryClientLicensee CategoryDeal TypesStagesSize ($M)Deal SubjectWeb LinkDeal IDPrimary DocEquity ($M)Maximum Share (%)Amendment DateTermination DateContractsPRsDeal SourceExclusivityDiseasesIndicationsTechnologiesSub TechnologiesTerritorySub-TerritoryCompound NameMOA CategoryMechanism of ActionMolecular TargetDrug Mode of Action
Upfront Cash ($M)
Upfront Equity ($M)
Contingent Equity ($M)
R&D Support ($M)
FTE Rate ($M)Loan ($M)
Dev / Reg Milestones ($M)
Other Milestones ($M)
Total Precommercial Payments ($M)
Sales Milestones ($M)
Deal Size ($M)
Upfront Share (%)
Dev Share (%)Sales Share (%)EFR$200M (%)EFR$500M (%)EFR$1B (%)Maximum Royalty (%)
Marketing Fee (%)
Transfer Price (%)
Manufacture Cost + (%)
Profit Split (%)Financial Term Explanations
2
06/2021Kindred Biosciences2013-21 IPOsElanco2013-21 IPOsAcquisition 440.00 Acquisition for $9.25/shLink19185Kindred_Elanco_0621_Acq_Full.pdfYesYesSEC FullExclusiveOther/MiscellaneousVeterinaryWorldwide 440.00 440.00 440.00 100.00 $9.25/sh 52% premium to FMV
3
06/2021Sirion BiotechPerkinElmerMid Tier PharmaAcquisitionAcquisition for undisclosed termsLink19092Sirion_PerkinElmer_062221.pdfYesPR
Cell Therapy - Stem Cells/Factors, Oligonucleotides
Gene Therapy
4
06/2021NovellusBrooklyn ImmunoTherapeuticsAcquisition, Letter of IntentPreclinical 125.00 Acquisition for cash and sharesLink19063Novellus_Brooklyn_061421.pdf 102.00 YesPR
Central Nervous System, Gastrointestinal, Respiratory
IBD - Crohn's Disease, IBD - Ulcerative Colitis, Multiple Sclerosis, Other Respiratory
Cell Therapy - Stem Cells/Factors 17.40 107.60 125.00 125.00 100.00
5
06/2021Khosla Ventures AcquisitionValo HealthAcquisitionAcquisition of SPAC for public listing of sharesLink19042Khosla_Valo_060920.pdfYesPR
6
06/2021SanofiTop PharmaStada ArzneimittelAsset PurchaseDivestiture of 16 Consumer Healthcare products commercialized in EuropeLink18957Sanofi_Stada_062821.pdfYesPROther/MiscellaneousOTC ProductsEurope
7
06/2021OrgentecSebiaAcquisitionDiagnosticAcquisition for undisclosed termsLink18934Orgentec_Sebia_063021.pdfYesPRAutoimmune/Inflammatory, HematologicDiagnostics
8
06/2021IVD VisionDCN DxAcquisitionDiagnosticAcquisition for undisclosed termsLink18933IVDVision_DCNDx_063021.pdfYesPRDiagnostics
9
06/2021iGenomXTwist Bioscience2013-21 IPOsAcquisition 35.00 Acquisition for cash and sharesLink18932iGenomX_Twist_063021.pdfYesPRGenomicsGene Sequencing 0.50 29.50 5.00 35.00 85.71
$29.5 million in Twist stock | $5M in Twist shares upon completion of certain milestones
10
06/2021OlimmuneScopus BioPharmaAcquisitionPreclinicalAcquisition for undisclosed termsLink18928Olimmune_Scopus_063021.pdfYesPRCancerBroad Focus CancerOligonucleotides
11
06/2021Chiasma2013-21 IPOsAmryt2013-21 IPOsAcquisitionApproved, Orphan IndicationMerger agreement in all-stock transactionLink18926Chiasma_Amryt_0521_Acq_Full.pdfYesYesSEC Full
Cardiovascular, Endocrinological & Metabolic, Other/Miscellaneous
Genetic Disorders, Hypercholesterolemia, Other Endocrinological & Metabolic
Oligonucleotides, PeptidesGene Therapy
12
06/2021Quintara DiscoveryFrontage LaboratoriesAcquisitionAcquisition for undisclosed termsLink18925Quintara_FrontageLabs_062821.pdfYesPR
13
06/2021DNA Diagnostics CenterEurofins ScientificAcquisitionDiagnosticAcquisition for undisclosed termsLink18924DNADiagnostics_Eurofins_062821.pdfYesPRDiagnostics
14
06/2021FS Development CorpPardes BiosciencesAcquisitionAcquisition of SPAC for public listing of sharesLink18923FSDevelopment_Pardes_062921.pdfYesPRInfectious-ViralCoronavirus
15
06/2021Applied Pharma ResearchRelief TherapeuticsAcquisitionApproved, Orphan Indication 72.00 Acquisition for cash and sharesLink18922APR_Relief_062921.pdfYesPR
Endocrinological & Metabolic, Other/Miscellaneous
Genetic Disorders, Other Endocrinological & Metabolic
23.00 49.00 72.00 31.94
CHF 21.5 million in cash (US$23M) | CHF 45 million (US$49M) in Relief common registered shares (when issued and listed). | Additional contingent payments in a combination of cash and Relief common registered shares upon achievement of undisclosed milestones
16
06/2021VoluntisAptarGroupAcquisitionAcquisition for $10.35/shareLink18918Voluntis_Aptar_062221.pdfYesPR 61.50 €8.70 per share for approximately €50.8 million ($61.5M)
17
06/2021Osmotica2013-21 IPOsAlora PharmaceuticalsAsset Purchase 170.00 Divestiture of portfolio of legacy products and Georgia-based manufacturing facilityLink18906Osmotica_Alora_062521.pdfYesPR 110.00 170.00 64.71 $60M in undisclosed milestones
18
06/2021Teneobio, TeneoOneAbbVieTop PharmaAcquisitionPhase I, Orphan Indication 650.00 Acquisition for undisclosed termsLink18898TeneoOne_AbbVie_062421.pdfYesPRCancerMultiple MyelomaMonoclonalsBispecific 650.00
19
06/2021Cerecor2013-21 IPOsES TherapeuticsAsset PurchasePreclinicalDivestiture of non-core neurology pipeline assets (COMTi platform, including CERC-406)Link18884SanfordBurnham_Cerecor_062321.pdfYesPRPsychiatricDepression & ManiaSyntheticsSmall MoleculeCERC-406Enzyme Inhibitorcatechol-O-methyl-transferase (COMT)Inhibitor
20
06/2021Cerecor2013-21 IPOsAlto NeuroscienceAsset PurchasePhase IIDivestiture of non-core neurology pipeline assets (compounds used in CERC-301)Link18883SanfordBurnham_Cerecor_062321.pdfYesPRPsychiatricDepression & ManiaSyntheticsSmall Moleculerislenemdaz, CERC-301, MK-0657Antidepressants/AntipsychoticsNMDA receptor subunit 2B (NR2B)Antagonist
21
06/2021AldevronDanaherAcquisition 9,600.00 Acquisition for $9.6 billion in cashLink18877Aldevron_Danaher_061721.pdfYesPR 9,600.00
22
06/2021Piezo MotionBrain ScientificAcquisitionAcquisition for undisclosed termsLink18876PiezoMotion_BrainScientific_061621.pdfYesPR
23
06/2021Corlieve TherapeuticsuniQure2013-21 IPOsAcquisitionPreclinical, Orphan Indication 298.10 Acquisition for cashLink18873Corlieve_uniQure_062221.pdfYesPRCentral Nervous SystemEpilepsyOligonucleotidesGene Therapy 55.00 243.10 298.10 298.10 18.45 81.55
€46.3 million ($55 million) upfront in cash | €43.7 million (US$52.1M) for development milestones through phase 1/2 and another €160 million (US$191M) for phase 3 and approvals in the U.S. and EU.
24
06/2021HalioDxVeracyte2013-21 IPOsAcquisitionDiagnostic 318.00 Acquisition for cash and sharesLink18866HalioDx_Veracyte_060121.pdfYesPRCancerDiagnostics 180.00 137.00 318.00 99.69 €147 million in cash (US$180M) | €113 million in stock (US$138M)
25
06/2021Big Cypress Acquisition CorpSAB BiotherapeuticsAcquisitionAcquisition of SPAC for public listing of sharesLink18864BigCypress_SAB_062221.pdfYesPRMonoclonalsPolyclonals
26
06/2021Thimble Point Acquisition CorpPear TherapeuticsAcquisitionAcquisition of SPAC for public listing of sharesLink18863ThimblePoint_Pear_062221.pdfYesPR
Cancer, Cardiovascular, Central Nervous System, Gastrointestinal, Psychiatric
27
06/2021Lobo GeneticsEntheon BiomedicalAcquisition, WarrantAcquisition for sharesLink18841Lobo_Entheon_061621.pdfYesPR5,000,000 common shares
28
06/2021Astellas Pharma
Top Pharma, Japanese Pharma
Cheplapharm ArzneimittelAsset PurchaseApproved 113.00 Flemoxin, De-nol, Suprax, Unidox and Orbenine in Europe, Russia, CIS and AsiaLink18836Astellas_Cheplapharm_061621.pdfYesPR
Gastrointestinal, Infectious-Bacterial, Infectious-Viral
SyntheticsSmall MoleculeAsia, EuropeEastern Europe, Russia 113.00 Deal valued at €95 million (US$113M)
29
06/2021Cascade ChemistryAcetoAcquisitionAcquisition for undisclosed termsLink18748CascadeChemistry_Aceto_060221.pdfYesPR
30
06/2021Resolution MedicalArcline Investment ManagementAcquisitionAcquisition of majority stake for undisclosed termsLink18746Resolution_Arcline_060221.pdfYesPR
31
06/2021Otonomy2013-21 IPOsAlk-AbelloAsset PurchaseApprovedOtiprio (ciprofloxacin otic suspension) fluoroquinolone antibacterial to treat acute otitis externaLink18745Otonomy_ALK_060321.pdfYesPRInfectious-BacterialOther Infectious-BacterialSyntheticsSmall MoleculeOtiprio, ciprofloxacin otic suspension, OTO-201Anti-InflammatoryDNA gyraseInhibitor
32
06/2021TrasirAuris MedicalAcquisitionAcquisition for shares, proposed company name change to Altamira TherapeuticsLink18744Trasir_Auris_060321.pdfYesPRDrug Delivery, Oligonucleotidespurchase price comprises 0.77 million common shares of Auris Medical
33
06/2021AcenziaNovo Integrated SciencesAcquisition 15.00 Acquisition in all-share transaction valued at $15MLink18743Acenzia_Novo_060321.pdfYesPR 15.00
34
06/2021Noria Therapeutics, PSMA TherapeuticsBayerTop PharmaAcquisitionAcquisition of Noria Therapeutics and PSMA Therapeutics subsidiary for undisclosed termsLink18729Noria_PSMA_Bayer_060321.pdfYesPRCancerProstateSyntheticsSmall Molecule
35
06/2021MorphoSys2013-21 IPOsRoyalty Pharma2013-21 IPOsAsset Purchase, Equity 2,025.00 Monetization of Tremfya, otilimab, gantenerumab, pelabresib and CPI-0209 royaltiesLink18724MorphoSys_RoyaltyPharma_060221.pdfYesPR
Tremfya, guselkumab, CNTO-1959, otilimab, MOR103, GSK3196165, GSK165, gantenerumab, pelabresib, CPI-0610, CPI-0209
Anti-Inflammatory, Antidepressants/Antipsychotics
interleukin-23 subunit alpha, granulocyte macrophage colony-stimulating factor (GM-CSF), amyloid beta (A4) precursor protein (APP), enhancer of zeste homolog 2 (EZH2) (ENX1) (EZH1)
Antagonist, Inhibitor 1,425.00 100.00 350.00 150.00 2,025.00 75.31 7.41
$1.425 billion upfront | $100M of ordinary shares of MorphoSys | Up to $350M in Development Funding Bonds | $150M upon reaching certain milestones for otilimab, gantenerumab and pelabresib
36
06/2021Constellation Pharmaceuticals2013-21 IPOsMorphoSys2013-21 IPOsAcquisitionPhase III 1,700.00 Acquisition for $34/sh in cashLink18723Constellation_MorphoSys_0621_Acq_Full.pdfYesYesSEC FullCancer
Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors
SyntheticsSmall MoleculeWorldwide 1,700.00 1,700.00 1,700.00 100.00 $34/sh (70% premium)
37
05/2021SolitonAbbVie, Allergan
Top Pharma, Mid Tier Pharma
AcquisitionDevice 550.00 Acquisition for $22.60/sh in cashLink19183Soliton_Allergan_051021.pdfYesPRDermatologic, Other/MiscellaneousCosmetics, Other DermatologicDevice 550.00 550.00 550.00 100.00 $22.60/sh in cash
38
05/2021Environmental Impact Acquisition CorpDutch DNA BiotechAcquisitionAcquisition of SPAC for public listing of sharesLink19172Environmental_GreenLight_081021.pdfYesPR
39
05/2021Mallinckrodt, VtesseMid Tier PharmaMandosAsset PurchasePhase II, Orphan IndicationAdrabetadex (VTS-270) for Niemann-Pick Type C1 diseaseLink19017Mallinckrodt_Mandos_051921.pdfYesPROther/MiscellaneousGenetic DisordersSyntheticsSmall Moleculeadrabetadex, VTS-270cholesterolModulator
40
05/2021Myriad GeneticsIQVIA, Q2 SolutionsAsset Purchase 198.00 Acquisition of Myriad RBM for undisclosed termsLink19014MyriadGenetics_Q2Solutions_052421.pdfYesPR 198.00
41
05/2021Montes Archimedes AcquisitionRoivant SciencesAcquisitionAcquisition of SPAC for public listing of sharesLink19005Roivant_Montes_0521_Acq_Full.pdfYesYesSEC Full
42
05/2021Myriad GeneticsLabCorpAsset PurchaseDiagnosticAcq. of select operating assets and IP from autoimmune business unit, including Vectra assayLink19004MyriadGenetics_Labcorp_050321.pdfYesPRAutoimmune/Inflammatory
Broad Focus Autoimmune/Inflammatory, Rheumatoid Arthritis
Diagnostics
43
05/2021Immunodiagnostic SystemsPerkinElmerMid Tier PharmaAcquisition 155.00 Acquisition for $155M in cashLink18894Immunodiagnostic_PerkinElmer_051721.pdfYesPR 155.00 155.00 100.00
44
05/2021Locust Walk AcquisitioneFFECTOR Therapeutics2013-21 IPOsAcquisitionAcquisition of SPAC for public listing of sharesLink18889LocustWalk_eFFECTOR_052721.pdfYesPRCancerSyntheticsSmall Molecule
45
05/2021Vigene BiosciencesCharles River Laboratories1991-2001 IPOsAcquisition 350.00 Acquisition to $292.5M in cashLink18685Vigene_CharlesRiver_051721.pdfYesPROligonucleotidesGene Therapy 292.50 350.00 83.57
$292.5M in cash | Contingent additional payments of up to $57.5M based on future performance
46
05/2021VecturaThe Carlyle GroupAcquisitionApproved 1,360.00 Acquisition for cashLink18684Vectura_Carlyle_052621.pdfYesPRRespiratoryDrug DeliveryOther 1,360.00 1,360.00 1,360.00 100.00
£958 million ($1.36 billion) - shareholders receive 136 pence in cash plus a dividend of 19 pence for each share under the terms of the offer
47
05/2021Aerpio PharmaceuticalsAADiAcquisition, CVR, EquityFiled, Orphan IndicationReverse merger agreement, combined public company to be named Aadi BioscienceLink18668Aerpio_Aadi_0521_Acq_Full.pdfYesYesSEC FullExclusiveCancerSolid Tumors, Other CancerSyntheticsSmall MoleculeWorldwide
Aadi owns 66.8% of OS (pre-PIPE) | 100% of payments rec'd under 6/18 Gossamer Bio agmt
48
05/2021Dutch DNA BiotechGinkgo BioworksAcquisitionAcquisition for cash and sharesLink18654DutchDNA_Ginkgo_051721.pdfYesPR
49
05/2021Soaring Eagle Acquisition CorpGinkgo BioworksAcquisitionAcquisition of SPAC for public listing of sharesLink18653Ginkgo_SoaringEagle_051121.pdfYesPR
50
05/2021Concert Pharmaceuticals2013-21 IPOsVertexMajor BiotechAsset PurchasePhase II, Orphan Indication 32.00 Buyout of future VX-561 (deutivacaftor) milestonesLink18642Concert_Vertex_051721.pdfYesPRRespiratoryCystic FibrosisSyntheticsSmall Molecule
deutivacaftor, CTP-656, VX-561, D-ivacaftor, deuterated ivacaftor, C-10355, C-10358
cystic fibrosis transmembrane conductance regulator (CFTR)Stimulant 32.00 32.00 32.00 100.00
51
05/2021Kinos Medicalrestor3dAcquisitionMerger agreementLink18635Kinos_restor3d_051421.pdfYesPRBone Disease
52
05/2021Nexcelom BiosciencePerkinElmerMid Tier PharmaAcquisition 260.00 Acquisition for $260M in cashLink18631Nexcelom_PerkinElmer_051221.pdfYesPR 260.00 260.00 100.00
53
05/2021Kuur TherapeuticsAthenex2013-21 IPOsAcquisition, CVR, Equity 185.00 Acquisition of CAR-NKT cell immunotherapies companyLink18604Athenex_Kuur_0521_Acq_Full.pdfYesYesSEC RedactedExclusiveCancerLeukemia, Solid TumorsCell Therapy - Stem Cells/FactorsWorldwide 70.00 185.00 185.00 37.84 $115M in agg milestones, per Athenex's 3Q21
54
05/2021InivataNeoGenomicsAcquisitionDiagnostic 415.00 Acquisition for cash of liquid biopsy co for cancer diagnosisLink18602NeoGenomics_Inivata_0521_Acq_Full.pdfYesYesSEC FullExclusiveCancerWorldwide 415.00 415.00 415.00 100.00 $25M in 5/20, plus add'l $390M in 5/21
55
05/2021FF Gene BiotechFulgent Genetics2013-21 IPOsAcquisitionAcq. of majority stake and controlling ownership of Chinese JV entity FF Gene BiotechLink18600FFGene_Fulgent_051021.pdfYesPRGenomicsGene Sequencing
56
05/2021LifeSci Acquisition CorpScience 37AcquisitionAcquisition of SPAC for public listing of sharesLink18595Science37_LifeSciAcquisition_050721.pdfYesPR
57
05/2021Jasper TherapeuticsAmplitude HealthcareAcquisitionPhase IReverse merger agreement, combined public company to be named Jasper TherapeuticsLink18591Jasper_Amplitude_050621.pdfYesPRCancer, Transplantation
Leukemia, Multiple Myeloma, Stem Cell/Bone Marrow
MonoclonalsHumanized Abs
58
05/2021GamaMabs PharmaExelixis1991-2001 IPOsAsset PurchasePhase IIAMHR2 humanized antibody program for cancer including murlentamab (GM-102)Link18579GamaMabs_Exelixis_050421.pdfYesPRCancerBroad Focus CancerMonoclonalsHumanized Absmurlentamab, GM-102Immuno-Oncologyanti-Mullerian hormone receptor type II (AMHR2)Antagonist 5.00
59
04/2021AvalunBiosynexAcquisitionDiagnosticAcquisition for undisclosed termsLink18891Avalun_Biosynex_041321.pdfYesPRDiagnostics
60
04/2021NeurMedixBioVieAsset PurchasePhase III 3.00 Acquisition of portfolio of biopharmaceutical assets including NE3107 for Alzheimer's diseaseLink18819BioVie_NeurMedix_0421_Asset_Full.pdf05/2021YesYesSEC FullCancer, Central Nervous System
Alzheimer's Disease, Multiple Myeloma, Parkinson's Disease, Prostate
SyntheticsSmall Molecule 3.00
61
04/2021ZebiAI TherapeuticsRelay Therapeutics2013-21 IPOsAcquisition, CVR, EquityDiscovery 270.00 Acquisition for cash, equity & CVRLink18704Relay_ZebiAI_0421_Acq_Full.pdf 65.00 YesYesSEC FullExclusiveBioinformaticsWorldwide 20.00 65.00 85.00 100.00 270.00 270.00 31.48 31.48 10% of partnering rev, up to $100M max
62
04/2021PPD2013-21 IPOsThermo Fisher ScientificAcquisition 17,400.00 Acquisition for cashLink18612PPD_ThermoFisher_0421_Acq_Full.pdfYesYesSEC FullExclusiveWorldwide 17,400.00 17,400.00 17,400.00 100.00 $47.50/sh
63
04/2021Dicerna Pharmaceuticals2013-21 IPOsRoyalty Pharma2013-21 IPOsAsset Purchase, CVR 240.00 Oxlumo (lumasiran) royalty interestLink18610Dicerna_RoyaltyPharma_0421_Asset_Full.pdfYesYesSEC FullExclusiveOxlumo, lumasiran, ALN-GO1, WHO 10684, ALN-65585, AD-65585Enzyme Inhibitorhydroxyacid oxidase 1Inhibitor 180.00 180.00 60.00 240.00 75.00 25.00
64
04/2021ZikaniEloxx PharmaceuticalsAcquisition, EquityAcquisition for sharesLink18609Eloxx_Zikani_0421_Acq_Full.pdfYesYesSEC FullExclusiveWorldwide7.6M Eloxx shares
65
04/2021Myriad GeneticsCastle Biosciences2013-21 IPOsAsset PurchaseDiagnostic 32.50 Acquisition of Myriad myPath Melanoma, LLC, Laboratory for $32.5M in cashLink18556Myriad_Castle_042721.pdfYesPRCancerMelanoma 32.50 32.50
66
04/2021Amplyx PharmaceuticalsPfizerTop PharmaAcquisitionPhase IIAcquisition for undisclosed termsLink18546Amplyx_Pfizer_042821.pdfYesPRInfectious-Miscellaneous, Infectious-ViralFungalSyntheticsSmall Molecule
67
04/2021KCASVitruvian PartnersAcquisitionAcquisition of majority stake for undisclosed termsLink18519KCAS_Vitruvian_041521.pdfYesPR
68
04/2021Consonance-HFW AcquisitionSurrozenAcquisitionAcquisition of SPAC for public listing of sharesLink18514Surrozen_Consonance._041521.pdfYesPRMonoclonals
69
04/2021Lilly, Dermira
Top Pharma, 2013-21 IPOs
Fortress Biotech, Journey MedicalAsset PurchaseApprovedQbrexza (glycopyrronium) to treat primary axillary hyperhidrosis in the USLink18509
JourneyMed(Fortress)_Dermira(Lilly)_0321_Asset.pdf
YesYesSEC RedactedDermatologicOther DermatologicDrug Delivery, SyntheticsSmall Molecule, TopicalNAFTAUSQbrexza, glycopyrronium topical cloth, DRM-04B, DRM04
muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M3, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M5
Antagonist
70
03/2021CM Life Sciences IISomaLogic2013-21 IPOsAcquisitionAcquisition of SPAC for public listing of sharesLink19194CMLifeSciences_SomaLogic_032921.pdfYesPRGenomicsProteomics
71
03/2021Research Alliance CorpPoint BiopharmaAcquisitionAcquisition of SPAC for public listing of sharesLink18930ResearchAlliance_Point_031521.pdfYesPRCancer
72
03/2021Resolution BioscienceAgilent TechnologiesMid Tier PharmaAcquisitionDiagnostic 695.00 Acquisition for cashLink18914ResolutionBioscience_Agilent_030221.pdfYesPRCancerDiagnostics 550.00 145.00 695.00 79.14 20.86 $145M based on achieving future performance milestones.
73
03/2021IpsenMid Tier PharmaFusion Pharmaceuticals2013-21 IPOsAsset Purchase, CVR, EquityPhase I 505.20 FPI-2059 (IPN-1087 small molecule targeting neurotensin receptor 1 NTSR1) for solid tumorsLink18491Fusion_Ipsen_0321_Asset.pdfYesYesSEC RedactedExclusiveCancerSolid TumorsSyntheticsSmall MoleculeWorldwideFPI-2059, IPN-1087neurotensin receptor 1 (NTSR1) 81.70 81.70 423.50 505.20 16.17 83.83
350M Euros, per Fusion's 2020 10-K | 400K Fusion shares | 200K add'l Fusion shares | low single-digit royalties, per Fusion's 2020 10-K | 67.5M Euros, per Fusion's 2020 10-K
74
03/2021Rodeo TherapeuticsAmgenMajor Biotech, Top PharmaAcquisitionPreclinical 717.00 Acquisition in cash transactionLink18466Rodeo_Amgen_033021.pdfYesPRAutoimmune/InflammatorySyntheticsSmall Molecule 55.00 717.00 7.67 $666M in undisclosed milestones
75
03/2021NovitiumANI PharmaceuticalsAcquisition, CVR, EquityApproved 210.00 Acquisition for cash and sharesLink18463ANI_Novitium_0321_Acq_Full.pdf 74.00 YesYesSEC FullExclusiveGenericsWorldwide 89.50 74.00 163.50 46.50 210.00 77.86 22.14 $46.5M in Earn-out payments
76
03/2021Hutchison China MediTechGL CapitalAsset Purchase 169.00 Acquisition of interest in OTC drug joint venture businessLink18425Hutchmed_GLCapital_032421.pdfYesPROther/MiscellaneousOTC Products 169.00
77
03/2021Vestas PharmaPerrigoAsset PurchaseApproved 1,550.00 Gnererics Rx businessLink18402Perrigo_Vestas_0321_Asset_Full.pdfYesYesSEC FullExclusiveGenerics 1,550.00 1,550.00 1,550.00 100.00
78
03/2021UroGen Pharma2013-21 IPOsRTW InvestmentsAsset Purchase 75.00 Jelmyto and UGN-102 royalty interestLink18394UroGen_RTW_031821.pdfYesPRCancerBladderDrug Delivery, SyntheticsSmall Molecule, Sustained ReleaseJelmyto, mitomycin 75.00
79
03/2021BFS MolecularCareDx2013-21 IPOsAcquisitionAcquisition for undisclosed termsLink18385BFS_CareDx_031721.pdfYesPRBioinformatics
80
03/2021Intec Pharma2013-21 IPOsDecoy BiosystemsAcquisition, EquityPreclinicalAcquisition for sharesLink18378Intec_Decoy_0321_Acq_Full.pdfYesYesSEC FullExclusiveCancer, Infectious-ViralWorldwideDecoy shareholders own 75% of combined OS
81
03/2021GenMark Diagnostics2003-12 IPOsRocheTop PharmaAcquisitionDiagnostic 1,800.00 Acquisition for $24.05/share in all-cash transactionLink18371Genmark_Roche_0321_Acq_Full.pdfYesYesSEC FullExclusiveInfectious-Bacterial, Infectious-ViralDiagnosticsWorldwide 1,800.00 1,800.00 1,800.00 100.00 $24.05/share
82
03/2021Maverick TherapeuticsTakedaTop PharmaAcquisitionPhase I, Preclinical 525.00 Acquisition for $525MLink18332Maverick_Takeda_030921.pdfYesPRCancerSolid TumorsCell Therapy - Stem Cells/Factors 525.00 525.00
$525M in upfront payment, development and regulatory milestones, purchase price subject to adjustments including for Takeda’s current equity stake and Maverick debt.
83
03/2021Five Prime2013-21 IPOsAmgenMajor Biotech, Top PharmaAcquisition 1,900.00 Acquisition for cashLink18306Amgen_FivePrime_0321_Acq_Full.pdfYesYesSEC FullExclusiveWorldwide 1,900.00 1,900.00 1,900.00 100.00 $38/sh
84
02/2021ShiseidoCVC CapitalAsset Purchase, Joint VentureAcquisition of personal care business, formation of Fine Today Shiseido joint ventureLink18972Shiseido_CVC_020321.pdfYesPROther/MiscellaneousCosmetics, OTC Products
85
02/2021Leisure Acquisition CorpEnsysce BiosciencesAcquisitionMerger with SPAC for public listing of sharesLink18931LeisureAcq_Ensysce_020121.pdfYesPRCentral Nervous System, PsychiatricAddiction, Pain
86
02/2021GlaxoSmithKlineTop PharmaNovartis, SandozTop PharmaAsset PurchaseApproved 500.00 Acquisition of Cephalosporin antibiotics business including Zinnat, Zinacef and Fortum brandsLink18806GSK_Sandoz_020121.pdfYesPRInfectious-BacterialBroad Focus Infectious-BacterialSyntheticsSmall Molecule 350.00 500.00 70.00 Additional milestone payments up to $150M
87
02/2021Decipher BiosciencesVeracyte2013-21 IPOsAcquisition, EquityApproved, Diagnostic 600.00 Acquisition for cash and sharesLink18703Veracyte_Decipher_0221_Acq_Full.pdf 350.00 YesYesSEC FullExclusiveCancerDiagnosticsWorldwide 250.00 350.00 600.00 600.00 100.00 $350M in Veracyte shares @ $54.30 per share
88
02/2021Delphi GeneticsCatalent Pharma SolutionsAcquisitionAcquisition for undisclosed termsLink18629Delphi_Genetics_022321.pdfYesPR
Cell Therapy - Stem Cells/Factors, Oligonucleotides
Gene Therapy
89
02/2021WeSana HealthDebut DiamondsAcquisitionReverse merger, combined public company to be named Wesana Health HoldingsLink18626Wesana_DebutDiamonds_020221.pdfYesPRCentral Nervous System, Psychiatric
90
02/2021ConturaAxonicsAcquisition, CVR, Equity, Supply 235.00 Acq for cash and sharesLink18603Axonics_Contura_0221_Acq.pdf 59.00 YesSEC RedactedExclusive 141.00 59.00 200.00 35.00 235.00 85.11 14.89 1.1M Axonics shares
91
02/2021Pandion Therapeutics2013-21 IPOsMerckTop PharmaAcquisitionPhase I 1,850.00 Acquisition for cashLink18472Pandion_Merck_0221_Acq_Full.pdfYesYesSEC FullExclusiveAutoimmune/InflammatoryBroad Focus Autoimmune/Inflammatory 1,850.00 1,850.00 1,850.00 100.00 $60/sh
92
02/2021PRA Health SciencesICONAcquisition, Equity 12,000.00 Acquisition for cash and sharesLink18403PRAHealth_Icon_0221_Acq_Full.pdfYesYesSEC FullExclusive 12,000.00 12,000.00 $80/sh | 0.4125 shs of ICON per PRA share (34% of OS)
93
02/2021HistoCyte LaboratoriesAtlas AntibodiesAcquisitionAcquisition for undisclosed termsLink18251HistoCyte_Atlas_021521.pdfYesPR
94
02/2021DDS LabRoundTable HealthcareAcquisitionAcquisition for undisclosed termsLink18250DDS_RoundTable_021821.pdfYesPRDental/Oral
95
02/2021Beacon DiscoveryEurofins ScientificAcquisitionAcquisition for undisclosed termsLink18249BeaconDiscovery_Eurofins_021821.pdfYesPR
96
02/2021Vanamali OrganicsWavelength PharmaceuticalsAcquisitionAcquisition of majority stake in Vanamali OrganicsLink18248Vanamali_Wavelength_021821.pdfYesPR
97
02/2021
City of Hope, Translational Genomics Research Institute
Research InstitutionExact Sciences1991-2001 IPOsAsset Purchase, ResearchDiagnosticMinimal residual disease research collaboration, acq. of Ashion Analytics sequencing labLink18244TGen_ExactSciences_021621.pdfYesPRCancerLeukemia, Lymphoma, Multiple MyelomaGenomics
98
02/2021Newscope Capital, PharmaTherRevive TherapeuticsAsset Purchase 10.00 Acquisition of psilocybin assetsLink18234PharmaTher_Revive_021721.pdfYesPRCancer, Central Nervous SystempsilocybinAntidepressants/Antipsychoticsserotonin 2 receptorAgonist 10.00
99
02/2021SIDIS Corp, Propel LabsThermo Fisher ScientificAsset PurchaseAcquisition of cell sorting technology to expand cell analysis and flow cytometry portfolioLink18232Propel_ThermoFisher_021721.pdfYesPR
100
02/2021Alpha Healthcare Acquisition CorpHumacyteAcquisitionAcquisition of SPAC for public listing of sharesLink18230AlphaHealthcare_Humacyte_021721.pdfYesPR